E. D. Bateman (Cape Town, South Africa), K.F. Chung (London, United Kingdom)
Use of steroid receptor related STIP1 gene analysis as an asthma marker
H. Einisman, M.L. Reyes, J. Angulo, M. López-Lastra, J. Cerda, J.A. Castro-Rodríguez (Santiago, Chile)
|   |
Over-expression of Th17-related cytokines in bronchial and nasal submucosa in severe asthma
F.L.M. Ricciardolo, S. Benedetto, A. Di Stefano, G. Massaglia, B. Andreetto, G. Favatà, S. Conticello, G. Ciprandi (Orbassano, Veruno, Genova, Italy)
| |
Effect of corticosteroids on lymphocytes from severe asthma patients
M. Kaur, S. Reynolds, L. Smyth, S. Hall, K. Simpson, S. Fox, D. Singh (Stevenage, United Kingdom)
| |
Association of glucocorticoid receptor gene polymorphisms of R23K and R477H and steroid-resistant asthma in Chinese Han population
F. Zhao, H. Ouyang, C. Wu, Z. Li (Xi‘an, China)
| |
The effect of single-nucleotide polymorphism in IL-13 on airway hyperresponsiveness in asthmatics
Y. Utsumi, T. Miyamoto, K. Sekimura, N. Sasaki, N. Suzuki, Y. Nakamura, H. Kobayashi, K. Yamaucho (Morioka, Japan)
| |
Preventive effect of carbocysteine on exacerbation of asthma, GAIA randomised, placebo-controlled multi-centre study
H. Sano, Y. Tohda, M. Adachi, T. Fukuda, K. Ohta, S. Shoji, T. Miyamoto (Osaka-Sayma, Tokyo, Mibu, Kiyose, Japan)
| |
Effect of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthma
E.D. Bateman, P.M. O‘Byrne, W.W. Busse, J. Lötvall, E.R. Bleecker, L. Andersen, B. Haumann, L. Frith, J. Lim, L. Jacques, A. Woodcock (Cape Town, South Africa; Hamilton, Canada; Madison, Winston-Salem, Research Triangle Park, United States Of America; Gothenburg, Sweden; Uxbridge, United Kingdom)
| |
The value of magnesium sulfate nebulization in treatment of acute bronchial asthma during pregnancy
M. Badawy, I. Hasannen (Luxor, Sohag, Egypt)
| |
The effect of a single high dose vitamin D3 on neutrophilic airway inflammation in nonatopic asthma
J.C. de Groot, E.N. van Roon, H. Storm, E.H. Bel, A. ten Brinke (Leeuwarden, Amsterdam, Netherlands)
| |
Long-term efficacy of QMF149 in persistent asthma
R. Beasley, B. Lanier, Z. Márk, A. Moton, H.J. Kim, B. Hederer (Wellington, New Zealand; Fort Worth, East Hanover, United States Of America; Törökbálint, Hungary; Basel, Switzerland)
| |
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
I. Hall, M. Sarno, B. Disse, S. Atis, E. Beck, E. Bateman, H. Finnigan, C. Hallmann, A. Gupta, A. Fowler (Nottingham, Bracknell, United Kingdom; Ingelheim, Ruedersdorf, Biberach an der Riss, Germany; Mersin, Turkey; Cape Town, South Africa)
| |
Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients
G.J. Braunstahl, M. Deenstra, J. Canvin, P. Georgiou, G. Peachey, C.W. Chen (Rotterdam, Almere, Netherlands; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma
P.M. O‘Byrne, E.R. Bleecker, E.D. Bateman, W.W. Busse, A. Woodcock, R. Forth, T. Toler, L. Jacques, J. Lötvall (Hamilton, Canada; Winston-Salem, Madison, Research Triangle Park, United States Of America; Cape Town, South Africa; Manchester, Uxbridge, United Kingdom; Gothenburg, Sweden)
| |
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
A. Woodcock, E.R. Bleecker, J. Lötvall, P.M. O‘Byrne, E.D. Bateman, H. Medley, A. Ellsworth, L. Jacques, W.W. Busse (Manchester, Uxbridge, Madison, United Kingdom; Winston-Salem, Research Triangle Park, United States Of America; Gothenburg, Sweden; Hamilton, Canada; Cape Town, South Africa)
| |
Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
H. Kerstjens, R. Dahl, E. Beck, M. Vandewalker, M. Engel, R. Sigmund, W. Seibold, P. Moroni-Zentgraf, E. Bateman (Groningen, Netherlands; Aarhus C, Denmark; Rüdersdorf Brandenburg, Biberach an der Riss, Ingelheim am Rhein, Germany; Columbia, United States Of America; Cape Town, South Africa)
| |
Usability evaluation of NEXThaler® versus Diskus® and Turbuhaler®
P.G. Linnane, T. Voshaar, M. Spinola, A. Campanini, D. Lock, M. Scuri, B. Ronca, A.S. Melani (Parma, Siena, Italy; Moers, Germany; London, United Kingdom)
| |
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
F. Sergio, C. Francisco, A. Muraro, F. Kanniess (Parma, Italy; Reinfeld, Germany)
| |
Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation
W. Azouz, M. El-Soussi, H. Chrystyn (Huddersfield, United Kingdom; Tripoli, Libyan Arab Jamahiriya)
| |